Specifically, IC with cisplatin and 5-fluorouracil, CCRT, and considerable maintenance with IFN-β were recommended for selected pediatric patients with NPC at high risk and advanced stage.12 Additionally, 15 patients (3.2%) received RT alone in the IMRT era in the current study. The gene discussed is IFNB1; the disease is nasopharyngeal carcinoma.